WO2007103765A3 - Treatment with cyclosporin a - Google Patents

Treatment with cyclosporin a Download PDF

Info

Publication number
WO2007103765A3
WO2007103765A3 PCT/US2007/063126 US2007063126W WO2007103765A3 WO 2007103765 A3 WO2007103765 A3 WO 2007103765A3 US 2007063126 W US2007063126 W US 2007063126W WO 2007103765 A3 WO2007103765 A3 WO 2007103765A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclosporin
treatment
keratoconus
topically
vision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/063126
Other languages
French (fr)
Other versions
WO2007103765A2 (en
Inventor
Rhett M Schiffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to DK07757768.2T priority Critical patent/DK1991249T3/en
Priority to AU2007223361A priority patent/AU2007223361B2/en
Priority to CA2644241A priority patent/CA2644241C/en
Priority to EP07757768.2A priority patent/EP1991249B1/en
Priority to ES07757768.2T priority patent/ES2485416T3/en
Publication of WO2007103765A2 publication Critical patent/WO2007103765A2/en
Publication of WO2007103765A3 publication Critical patent/WO2007103765A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein is a method comprising administering cyclosporin A topically to an eye of a person for the purpose of treating or preventing loss of vision from keratoconus.
PCT/US2007/063126 2006-03-03 2007-03-02 Treatment with cyclosporin a Ceased WO2007103765A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK07757768.2T DK1991249T3 (en) 2006-03-03 2007-03-02 CYCLOSPORIN A FOR TREATMENT OF VISIBILITY
AU2007223361A AU2007223361B2 (en) 2006-03-03 2007-03-02 Treatment with cyclosporin A
CA2644241A CA2644241C (en) 2006-03-03 2007-03-02 Treatment with cyclosporin a
EP07757768.2A EP1991249B1 (en) 2006-03-03 2007-03-02 Cyclosporin a for treating loss of vision
ES07757768.2T ES2485416T3 (en) 2006-03-03 2007-03-02 Ciclosporin A to treat vision loss

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77912006P 2006-03-03 2006-03-03
US60/779,120 2006-03-03

Publications (2)

Publication Number Publication Date
WO2007103765A2 WO2007103765A2 (en) 2007-09-13
WO2007103765A3 true WO2007103765A3 (en) 2007-11-01

Family

ID=38371064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/063126 Ceased WO2007103765A2 (en) 2006-03-03 2007-03-02 Treatment with cyclosporin a

Country Status (7)

Country Link
US (2) US7557082B2 (en)
EP (1) EP1991249B1 (en)
AU (1) AU2007223361B2 (en)
CA (1) CA2644241C (en)
DK (1) DK1991249T3 (en)
ES (1) ES2485416T3 (en)
WO (1) WO2007103765A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2667945T3 (en) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
AU2010327321A1 (en) * 2009-12-02 2012-07-12 The University Of Sydney Diagnostic and therapeutic methods for corneal ectasia following refractive surgery, keratoconus or pellucid degeneration
JP2015519368A (en) 2012-06-01 2015-07-09 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Cyclosporine A analog
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001772A1 (en) * 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
GB2224205A (en) * 1988-10-26 1990-05-02 Sandoz Ltd Ophthalmic cyclosporin compositions
WO2003030834A2 (en) * 2001-10-12 2003-04-17 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of lung diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001772A1 (en) * 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
GB2224205A (en) * 1988-10-26 1990-05-02 Sandoz Ltd Ophthalmic cyclosporin compositions
WO2003030834A2 (en) * 2001-10-12 2003-04-17 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of lung diseases

Also Published As

Publication number Publication date
WO2007103765A2 (en) 2007-09-13
EP1991249A2 (en) 2008-11-19
US20090264348A1 (en) 2009-10-22
CA2644241A1 (en) 2007-09-13
CA2644241C (en) 2015-07-28
AU2007223361B2 (en) 2013-07-18
US20070207951A1 (en) 2007-09-06
ES2485416T3 (en) 2014-08-13
EP1991249B1 (en) 2014-05-07
US8207129B2 (en) 2012-06-26
US7557082B2 (en) 2009-07-07
DK1991249T3 (en) 2014-07-21
AU2007223361A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2007117971A3 (en) Ocular allergy treatments
WO2007103765A3 (en) Treatment with cyclosporin a
HK1198631A1 (en) Prevention and treatment of ocular conditions
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2010030785A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011112766A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2008070726A3 (en) Treatment for dry eye
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
WO2009111633A3 (en) Mercaptan and seleno-mercaptan compounds and methods of using them
WO2011112731A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
WO2012170947A3 (en) Methods for modulating factor 12 expression
WO2007105203A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2007120817A3 (en) Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
WO2010120431A3 (en) Methods for the prevention and treatment of burn injuries and secondary complications
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2012016000A3 (en) Preservative free brimonidine and timolol solutions
WO2013055385A3 (en) Methods of treating age related disorders
WO2011076368A3 (en) Topical ophthalmic peptide formulation
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
WO2005016270A3 (en) Methods for treatment of dermatological conditions
WO2009126695A3 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2644241

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007757768

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007223361

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007223361

Country of ref document: AU

Date of ref document: 20070302

Kind code of ref document: A